Drug Trial Radar · NCT06459180
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
686
Planned (sponsor's estimate)
Start
Jul 24, 2024
Primary completion
Jun 15, 2028
Study completion Jun 15, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
- First posted
- Jun 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 portion. The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.
Conditions
- Cervical Cancer
Interventions
Sacituzumab TirumotecanBiological
IV infusion
PemetrexedDrug
IV infusion
Tisotumab VedotinBiological
IV infusion
TopotecanDrug
IV infusion
VinorelbineDrug
IV infusion
GemcitabineDrug
IV infusion
IrinotecanDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) in Sacituzumab Tirumotecan Run-inTime frame: Up to approximately 46 months
- Number of Participants Experiencing One or More Adverse Events (AEs) in Sacituzumab Tirumotecan Run-inTime frame: Up to approximately 46 months
- Number of Participants Discontinuing Study Treatment Due to an AE in Sacituzumab Tirumotecan Run-inTime frame: Up to approximately 46 months
- Overall Survival (OS) in Phase 3 PortionTime frame: Up to approximately 35 months
Locations
240 sites in 32 countries. Site status is shown where the registry gives one.
USA Mitchell Cancer Institute-Clinical Trials ( Site 4126)
Mobile, Alabama
Providence Alaska Medical Center ( Site 4137)
Anchorage, Alaska
HonorHealth (HH) ( Site 8002)
Phoenix, Arizona
Arizona Oncology Associates - HOPE ( Site 8001)
Tucson, Arizona
Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 4125)
La Jolla, California
UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4105)
Los Angeles, California
Hoag Memorial Hospital Presbyterian ( Site 4104)
Newport Beach, California
Mount Sinai Comprehensive Cancer Center ( Site 4143)
Miami Beach, Florida
Advent Health ( Site 4140)
Orlando, Florida
Florida Cancer Specialists East ( Site 7001)
West Palm Beach, Florida
Northside Hospital ( Site 4127)
Atlanta, Georgia
Georgia Cancer Center at Augusta University ( Site 4112)
Augusta, Georgia
Lewis Cancer and Research Pavilion ( Site 4114)
Savannah, Georgia
University Medical Center New Orleans ( Site 4132)
New Orleans, Louisiana
Willis Knighton Medical Center ( Site 4101)
Shreveport, Louisiana
The Center of Hope ( Site 4106)
Reno, Nevada
Holy Name Medical Center ( Site 4117)
Teaneck, New Jersey
Optimum Clinical Research Group ( Site 4138)
Albuquerque, New Mexico
Perlmutter Cancer Center NYU Langone Hospital - Long Island ( Site 4145)
Mineola, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 4121)
New York, New York
Duke Cancer Institute ( Site 4120)
Durham, North Carolina
University of Cincinnati Medical Center ( Site 4128)
Cincinnati, Ohio
The Ohio State University ( Site 4103)
Hilliard, Ohio
Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research ( Site 4116)
Tulsa, Oklahoma
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007)
Eugene, Oregon
Legacy Good Samaritan Medical Center-Oncology Clinical Research ( Site 4115)
Portland, Oregon
Sidney Kimmel Cancer Center - Jefferson Health ( Site 4142)
Philadelphia, Pennsylvania
Asplundh Cancer Pavilion ( Site 4113)
Willow Grove, Pennsylvania
The West Clinic, PLLC dba West Cancer Center ( Site 4108)
Germantown, Tennessee
Texas Oncology - Central/South Texas ( Site 8010)
Austin, Texas
Texas Oncology - DFW ( Site 8003)
Fort Worth, Texas
Houston Methodist Hospital OB/GYN ( Site 4102)
Houston, Texas
Texas Oncology - San Antonio ( Site 8006)
San Antonio, Texas
Texas Oncology - Northeast Texas ( Site 8009)
Tyler, Texas
Texas Oncology - Gulf Coast ( Site 8008)
Webster, Texas
University of Virginia Cancer Center ( Site 4123)
Charlottesville, Virginia
Inova Schar Cancer Institute ( Site 4139)
Fairfax, Virginia
Swedish Medical Center-Swedish Cancer Institute ( Site 4134)
Seattle, Washington
Hospital Aleman-Oncology ( Site 0100)
Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0109)
CABA, Argentina
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.